|
|
Post by sayhey24 on Aug 9, 2022 18:10:24 GMT -5
What do you mean "more aggressive approach to doctors to sell more Afrezza"? I might have missed that. What I heard is patients ask the doctors for afrezza and doctors don't prescribe. Thats should not be a surprise as afrezza is not really part of the standard of care. Mike said they had a promotional program which failed and they stopped it early after spending $6m but he gave no details. Was that Seeing is Believing campaign? They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. Aged - maybe, that was my thought but what did they spend $6M on? I thought they were going to big corporate GP practices to try and get them to start using by "Seeing and Believing" and then get them to start prescribing on a trial basis. I thought it was an attempt to side step the SoC until they can get their studies done. I was not expecting a small sales team going to targeted GPs costing $6M. I know gas wen tup but not that much. |
|
|
|
Post by sayhey24 on Aug 9, 2022 18:12:07 GMT -5
Was that Seeing is Believing campaign? They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. I have been shocked, the physicians do not care that the CGM shows these people are more controlled. next. Peppy - why are you shocked? Its not the standard of care. Why should the average doctor prescribe something when its not the SoC? |
|
|
|
Post by agedhippie on Aug 9, 2022 18:13:27 GMT -5
Was that Seeing is Believing campaign? They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. I have been shocked, the physicians do not care that the CGM shows these people are more controlled. next. You are making an assumption there. If they follow the label they are under-dosing (it's not 1:1 with RAA), skipping the second dose, and taking the dose at the wrong time in the meal. Doctors will follow the label unless they are 100% sure they know better, and since the label is from the largest scale trial to date that's where they land. |
|
|
|
Post by peppy on Aug 9, 2022 18:22:39 GMT -5
I have been shocked, the physicians do not care that the CGM shows these people are more controlled. next. Peppy - why are you shocked? Its not the standard of care. Why should the average doctor prescribe something when its not the SoC? Insulin is standard of Care for type ones. I know it is written as subq and basal. Type two's they will do anything to them. (for money) Make you pee out the glucose, make your intestinal lumen squeeze out some insulin, change your liver glycogen delivery etc, etc. "Section 3: Aims and Goals of Management of Type 1 Diabetes The aim of diabetes care and management is to support people with type 1 diabetes to live a long and healthy life. The management strategies to achieve this aim broadly include: Effectively delivering exogenous insulin to maintain glucose levels as close to the individual’s target range as is safely possible to prevent the development and progression of diabetes complications while: ∘ Minimizing episodes of hypoglyce mia, of all levels, including level 1 (<3.9 to ≥3.0 mmol/L [<70 to ≥54 mg/dL]) but, in particular, level 2 (<3.0 mmol/L [<54 mg/dL]) and level 3 (severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery) hypoglycemia, and preventing episodes of DKA, while treating these appropriately should they occur. Effectively managing cardiovascular risk factors." Why should a physician prescribe something that isn't standard of care? They don't because then they have to write letters and the physicians get telephone calls from the pharmacy manager saying, Bad boy, bad boy. or girl. |
|
|
|
Post by sayhey24 on Aug 9, 2022 18:23:11 GMT -5
I have been shocked, the physicians do not care that the CGM shows these people are more controlled. next. You are making an assumption there. If they follow the label they are under-dosing (it's not 1:1 with RAA), skipping the second dose, and taking the dose at the wrong time in the meal. Doctors will follow the label unless they are 100% sure they know better, and since the label is from the largest scale trial to date that's where they land. Aged - Mike said - "the patients are asking the doctors for afrezza and the doctors won't prescribe" There is a pretty good buzz starting with the T1s on social media about afrezza. Articles like Ginger Vieina's only help. There are lots of stories about the patients being told afrezza is not for them. If they can get the afrezza things like the facebook group will help with the cough and dosing. |
|
|
|
Post by agedhippie on Aug 9, 2022 18:26:16 GMT -5
Was that Seeing is Believing campaign? They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. Aged - maybe, that was my thought but what did they spend $6M on? I thought they were going to big corporate GP practices to try and get them to start using by "Seeing and Believing" and then get them to start prescribing on a trial basis. I thought it was an attempt to side step the SoC until they can get their studies done. I was not expecting a small sales team going to targeted GPs costing $6M. I know gas wen tup but not that much. The Q4 pilot was just a small sales team. The intention with the March launch was an expansion to all sales regions according to the Feb earnings call. |
|
|
|
Post by akemp3000 on Aug 9, 2022 18:31:57 GMT -5
Share price complaints are justified but there were a lot of positives on the call; 58% growth in revenue quarter-over-quarter, broke ground on needed plant expansion, "400 employees now" which is the most ever and "not a lot of turnover" (which used to not be the case), COGs will go down, V-Go was a good investment at $14M and is projected to bring in $18 to $20M annually. Negatives certainly exist but this company is on a good path. Just didn't want novices to get lost in the weeds  |
|
|
|
Post by sayhey24 on Aug 9, 2022 18:35:52 GMT -5
Peppy - why are you shocked? Its not the standard of care. Why should the average doctor prescribe something when its not the SoC? Insulin is standard of Care for type ones. I know it is written as subq and basal. Type two's they will do anything to them. (for money) Make you pee out the glucose, make your intestinal lumen squeeze out some insulin, change your liver glycogen delivery etc, etc. "Section 3: Aims and Goals of Management of Type 1 Diabetes The aim of diabetes care and management is to support people with type 1 diabetes to live a long and healthy life. The management strategies to achieve this aim broadly include: Effectively delivering exogenous insulin to maintain glucose levels as close to the individual’s target range as is safely possible to prevent the development and progression of diabetes complications while: ∘ Minimizing episodes of hypoglyce mia, of all levels, including level 1 (<3.9 to ≥3.0 mmol/L [<70 to ≥54 mg/dL]) but, in particular, level 2 (<3.0 mmol/L [<54 mg/dL]) and level 3 (severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery) hypoglycemia, and preventing episodes of DKA, while treating these appropriately should they occur. Effectively managing cardiovascular risk factors." Why should a physician prescribe something that isn't standard of care? They don't because then they have to write letters and the physicians get telephone calls from the pharmacy manager saying, Bad boy, bad boy. or girl. Yep - its a hassle and BP perks get cut off and thats for the T1s. For the T2s meal time insulin is the very last step. What GP is crazy enough to prescribe? Not many. I would have taken a megaphone to the ADA 2022 and had live "Seeing is Believing" and I would have made a scene. Mike was so proud of their booth, why? I also would be executing a plan which does the head to head trial with Mounjaro and tries to partner with Lilly. Can afrezza be a benefit with Mounjaro? Maybe. We know about 50% will stop using a GLP1 after 6 months. Mike needs a T2 plan. For the T1s the kids will blaze the trail and Mike seemed to say the kids trial was going well. |
|
|
|
Post by sayhey24 on Aug 9, 2022 18:42:45 GMT -5
Aged - maybe, that was my thought but what did they spend $6M on? I thought they were going to big corporate GP practices to try and get them to start using by "Seeing and Believing" and then get them to start prescribing on a trial basis. I thought it was an attempt to side step the SoC until they can get their studies done. I was not expecting a small sales team going to targeted GPs costing $6M. I know gas wen tup but not that much. The Q4 pilot was just a small sales team. The intention with the March launch was an expansion to all sales regions according to the Feb earnings call. OK - I expected a "Special Ops" team - , maybe 4 or 6 "guys" - Seal Team Six. This expert, highly trained team would be sent to targeted GP corporations around the country. I have no idea what they/Mike did nor what expansion to all sales regions means. The goal should have been to side step the SoC with targeted large GPs. Geisinger would have been a great target and they are the go to medical service in the Pottsville PA T2 hot spot. |
|
|
|
Post by cretin11 on Aug 9, 2022 18:50:31 GMT -5
Share pricing going down, looks like someone got a copy of the quarterly report early. Looks like you were right, nemzter. |
|
|
|
Post by agedhippie on Aug 9, 2022 18:51:14 GMT -5
You are making an assumption there. If they follow the label they are under-dosing (it's not 1:1 with RAA), skipping the second dose, and taking the dose at the wrong time in the meal. Doctors will follow the label unless they are 100% sure they know better, and since the label is from the largest scale trial to date that's where they land. Aged - Mike said - "the patients are asking the doctors for afrezza and the doctors won't prescribe" There is a pretty good buzz starting with the T1s on social media about afrezza. Articles like Ginger Vieina's only help. There are lots of stories about the patients being told afrezza is not for them. If they can get the afrezza things like the facebook group will help with the cough and dosing. The problem is that the " the patients are asking the doctors for afrezza and the doctors won't prescribe" statement is not quantified. What is the reason, and what are the numbers? This is a guess but I suspect the story goes; the doctors are endos and may well have tried on a couple of patients with poor results, and at that point they will stop (you don't keep throwing patients with a life threatening condition at a failing protocol). All following patients will be told that the patients they prescribed it for didn't do well so they cannot advise it. The patient's response is going to be to shrug and move on. So what is the fix? As I have been saying for ages this is going to take a large scale trial to produce the data. The trial can be with a revised protocol that increases doses, has a second dose, and is taken at the right time. Even throw in a Libre since they are freely available on insurance now. The data from that can rewrite the label and we stop getting doctors discouraged by a failing protocol. This is not rocket science, there is a reason manufactures continue large trials post launch, they want to improve the label. |
|
|
|
Post by sayhey24 on Aug 9, 2022 19:14:47 GMT -5
Aged - Mike said - "the patients are asking the doctors for afrezza and the doctors won't prescribe" There is a pretty good buzz starting with the T1s on social media about afrezza. Articles like Ginger Vieina's only help. There are lots of stories about the patients being told afrezza is not for them. If they can get the afrezza things like the facebook group will help with the cough and dosing. The problem is that the " the patients are asking the doctors for afrezza and the doctors won't prescribe" statement is not quantified. What is the reason, and what are the numbers? This is a guess but I suspect the story goes; the doctors are endos and may well have tried on a couple of patients with poor results, and at that point they will stop (you don't keep throwing patients with a life threatening condition at a failing protocol). All following patients will be told that the patients they prescribed it for didn't do well so they cannot advise it. The patient's response is going to be to shrug and move on. So what is the fix? As I have been saying for ages this is going to take a large scale trial to produce the data. The trial can be with a revised protocol that increases doses, has a second dose, and is taken at the right time. Even throw in a Libre since they are freely available on insurance now. The data from that can rewrite the label and we stop getting doctors discouraged by a failing protocol. This is not rocket science, there is a reason manufactures continue large trials post launch, they want to improve the label. Aged - you are right the statement is not quantified. From some social media sites potential patients are saying their doctor said no, afrezza is not for you. They seem to be like the "Soup Nazi". In a lot of cases new afrezza users are saying they are their doctors first afrezza patient. For the T1s "the fix" is the kids trial. If the kids trial ends up good and it seems like it is afrezza with the T1s should mimic what happened with the pumps. In the kids study they have been uping doses and "dosing as needed". For the T2s a totally different trial needs to be done. Affinity2 already showed afrezza to be superior but Sanofi wasted the moment and never followed up. As Mike said in the podcast it was done so long ago the "research community" has forgotten and has gotten busy with the GLP1s/DDP4s/SGLT2s. Mike needs to develop a plan on how to attack this market and then execute it. A new trial needs to be part of this. Clearly, whatever they did with "Seeing is Believing" was a failed mission and cost $6M. Maybe they can learn a lesson or two from this $6M failure. BTW - Mike said in the podcast they have already submitted for label changes. He did not say what changes they have requested. |
|
|
|
Post by letitride on Aug 9, 2022 20:31:33 GMT -5
Things that make me go Hmmmmmmmmmmmmm!
Mike was talking fast and mumbling not being clear on about everything, nervous maybe? Not the first time when he proverbially kicks the can down the road.
Mann group converts I believe that might have been that 10 million share end of day trades a few weeks back Why now who they planning to sell to and how soon.
Continued coverup of our deal with UTHR. Why? personally not buying the competition thing as I said in a previous post by next Qtr we could begin to extrapolate numbers based on sales. Unless there wont be a next Qtr?
The whole I am setting it up for a decade from now is BS IMO.
Im not big on buy out or in theory but I gotta say I have to go Hmmmmmmmmmmmmmmm!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2022 20:45:43 GMT -5
Things that make me go Hmmmmmmmmmmmmm! Mike was talking fast and mumbling not being clear on about everything, nervous maybe? Not the first time when he proverbially kicks the can down the road. Mann group converts I believe that might have been that 10 million share end of day trades a few weeks back Why now who they planning to sell to and how soon. Continued coverup of our deal with UTHR. Why? personally not buying the competition thing as I said in a previous post by next Qtr we could begin to extrapolate numbers based on sales. Unless there wont be a next Qtr? The whole I am setting it up for a decade from now is BS IMO. Im not big on buy out or in theory but I gotta say I have to go Hmmmmmmmmmmmmmmm! I think, that if you have 10 or 20 more years , before the big dirt nap, it could be a good investment... |
|
|
|
Post by brentie on Aug 9, 2022 20:48:33 GMT -5
|
|
